Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Krystal Biotech, Inc. operates as a biopharmaceutical company. The Company develops a proprietary gene therapy platform for the patients suffering from rare debilitating disorders. Krystal Biotech serves patients in the State of Pennsylvania.
Website: krystalbio.com


  • Good financial results growth rate 147.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (92.2%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 1.6% (LTM)
  • Share price is 133.8% higher than minimum and 30.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (31.4x vs 30.0x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $15.0 mln (-0.347% of cap.)

Key Financials (Download financials)

Ticker: KRYS
Share price, USD:  (-1.6%)147.61
year average price 167.47  


year start price 213.66 2024-07-28

max close price 213.66 2024-07-28

min close price 123.36 2025-05-28

current price 147.61 2025-07-27
Common stocks: 28 815 000

Dividend Yield:  0.0%
FCF Yield LTM: 1.6%
EV / LTM EBITDA: 31.4x
EV / EBITDA annualized: 24.0x
EV / Sales: 11.0x
Margin (EBITDA LTM / Revenue): 34.8%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 4 253
Net Debt ($m): -607
EV (Enterprise Value): 3 646
EBITDA LTM (млн $): 116
EV / LTM EBITDA: 31.4x
Price to Book: 4.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-10zacks.com

KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

2025-05-14marketbeat.com

Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore

2025-05-06seekingalpha.com

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

2025-05-06zacks.com

Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down

2025-05-06zacks.com

Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates

2025-03-17zacks.com

Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock

2025-03-08zacks.com

Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?

2025-03-08zacks.com

Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?

2025-02-28globenewswire.com

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

2025-02-24zacks.com

Why Krystal Biotech (KRYS) Might be Well Poised for a Surge
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-04 2024-08-05 2024-05-06 2024-02-26 2023-11-06 2023-08-07 2023-05-08 2023-02-27 2022-11-07
acceptedDate 2024-11-04 08:05:26 2024-08-05 08:08:09 2024-05-06 08:17:38 2024-02-26 07:49:58 2023-11-06 07:08:53 2023-08-07 07:07:31 2023-05-08 08:25:12 2023-02-27 07:14:24 2022-11-07 07:11:56
calendarYear 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q4 Q3
revenue 84M 70M 45M 42M 9M 0 0 0 0
costOfRevenue 7M 8M 2M 4M 223 000 1M 0 0 0
grossProfit 77M 62M 43M 38M 8M -1M 0 0 0
grossProfitRatio 0.92 0.886 0.947 0.896 0.974 0 0 0 0
researchAndDevelopmentExpenses 14M 16M 11M 11M 11M 12M 12M 11M 12M
generalAndAdministrativeExpenses 0 0 0 74M 24M 26M 24M 24M 20M
sellingAndMarketingExpenses 0 0 0 -50M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 29M 26M 26M 23M 24M 26M 24M 24M 20M
otherExpenses 13M 19M 15M 3M 223 000 0 13M 25M 0
operatingExpenses 55M 41M 37M 35M 35M 38M 36M 35M 31M
costAndExpenses 61M 49M 39M 39M 35M 38M 36M 35M 31M
interestIncome 0 7M 8M 8M 7M 5M 4M 3M 2M
interestExpense 0 0 0 -25M 0 0 25M 3M 2M
depreciationAndAmortization 2M 2M 2M -39 586 826 000 1M 26M 4M 3M
ebitda 31M 18M 20M 5M -26M -37M -23M -31M -29M
ebitdaratio 0.373 0.328 0.44 0.11 -3.038 0 0 0 0
operatingIncome 22M 21M -7M 3M -26M -38M -49M -35M -31M
operatingIncomeRatio 0.268 0.3 -0.148 0.074 -3.038 0 0 0 0
totalOtherIncomeExpensesNet 7M -5M -13M 8M 107M 5M 4M 3M 2M
incomeBeforeTax 30M 16M 932 000 11M 81M -33M -45M -32M -30M
incomeBeforeTaxRatio 0.355 0.228 0.021 0.253 9.437 0 0 0 0
incomeTaxExpense 3M 477 000 5M 2M -826 000 0 0 -3M -2M
netIncome 27M 16M 932 000 9M 81M -33M -45M -29M -28M
netIncomeRatio 0.324 0.222 0.021 0.206 9.437 0 0 0 0
eps 0.95 0.54 0.03 0.31 2.88 -1.25 -1.76 -1.15 -1.1
epsdiluted 0.91 0.53 0.03 0.3 2.79 -1.25 -1.76 -1.15 -1.1
weightedAverageShsOut 29M 29M 28M 28M 28M 27M 26M 25M 26M
weightedAverageShsOutDil 30M 30M 29M 29M 29M 27M 26M 25M 26M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-04 2024-08-05 2024-05-06 2024-02-26 2023-11-06 2023-08-07 2023-05-08 2023-02-27 2022-11-07
acceptedDate 2024-11-04 08:05:26 2024-08-05 08:08:09 2024-05-06 08:17:38 2024-02-26 07:49:58 2023-11-06 07:08:53 2023-08-07 07:07:31 2023-05-08 08:25:12 2023-02-27 07:14:24 2022-11-07 07:11:56
calendarYear 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q4 Q3
cashAndCashEquivalents 374M 346M 359M 358M 373M 276M 141M 162M 186M
shortTermInvestments 214M 214M 179M 174M 189M 202M 210M 217M 208M
cashAndShortTermInvestments 588M 560M 538M 532M 562M 478M 350M 379M 394M
netReceivables 97M 103M 46M 42M 9M 0 0 0 0
inventory 19M 12M 11M 7M 5M 0 0 0 0
otherCurrentAssets 9M 8M 6M 7M 5M 6M 5M 5M 3M
totalCurrentAssets 713M 683M 602M 588M 582M 484M 355M 384M 398M
propertyPlantEquipmentNet 163M 165M 167M 168M 171M 171M 171M 170M 166M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 106M 69M 84M 62M 37M 28M 5M 5M 13M
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 203 000 125 999 196 000 263 000 285 000 285 000 402 000 324 000 205 000
totalNonCurrentAssets 269M 235M 251M 230M 208M 200M 176M 175M 179M
otherAssets 0 1 0 0 0 0 0 0 0
totalAssets 982M 918M 853M 818M 790M 684M 532M 558M 576M
accountPayables 6M 5M 5M 4M 4M 4M 4M 4M 6M
shortTermDebt 1M 3M 1M 1M 2M 2M 2M 2M 2M
taxPayables 573 000 709 000 2M 2M 152 000 22 000 51 000 43 000 122 000
deferredRevenue 0 0 38M 1 19M 17M 0 0 0
otherCurrentLiabilities 82M 63M 3M 27M 2M 652 000 29M 23M 21M
totalCurrentLiabilities 90M 72M 48M 33M 28M 24M 35M 29M 28M
longTermDebt 6M 6M 6M 7M 7M 7M 7M 7M 8M
deferredRevenueNonCurrent 0 -588 000 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 761 000 588 000 0 -1 0 0 0 0 267 000
totalNonCurrentLiabilities 7M 7M 6M 7M 7M 7M 7M 7M 8M
otherLiabilities 0 0 0 1 0 0 0 0 0
capitalLeaseObligations 6M 8M 8M 7M 8M 9M 9M 9M 9M
totalLiabilities 96M 79M 54M 40M 34M 31M 42M 36M 36M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 0 0 0 0 0 0
retainedEarnings -226M -253M -269M -270M -279M -359M -326M -281M -249M
accumulatedOtherComprehensiveIncomeLoss 2M -634 000 -299 000 638 000 -382 000 -236 000 -154 000 -728 000 -1M
othertotalStockholdersEquity 1 110M 1 093M 1 068M 1 048M 1 035M 1 013M 816M 804M 791M
totalStockholdersEquity 886M 839M 799M 779M 756M 653M 490M 522M 541M
totalEquity 886M 839M 799M 779M 756M 653M 490M 522M 541M
totalLiabilitiesAndStockholdersEquity 982M 918M 853M 818M 790M 684M 532M 558M 576M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 982M 918M 853M 818M 790M 684M 532M 558M 576M
totalInvestments 320M 283M 263M 236M 225M 230M 215M 222M 221M
totalDebt 1M 8M 8M 8M 8M 9M 9M 9M 9M
netDebt -373M -338M -351M -350M -365M -267M -132M -153M -177M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS KRYS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-04 2024-08-05 2024-05-06 2024-02-26 2023-11-06 2023-08-07 2023-05-08 2023-02-27 2022-11-07
acceptedDate 2024-11-04 08:05:26 2024-08-05 08:08:09 2024-05-06 08:17:38 2024-02-26 07:49:58 2023-11-06 07:08:53 2023-08-07 07:07:31 2023-05-08 08:25:12 2023-02-27 07:14:24 2022-11-07 07:11:56
calendarYear 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q4 Q3
netIncome 27M 16M 932 000 9M 81M -33M -45M -32M -30M
depreciationAndAmortization 1M 2M 2M 2M 826 000 1M 705 000 1M 975 000
deferredIncomeTax 0 0 0 -46M -100M 0 0 0 0
stockBasedCompensation 13M 13M 9M 10M 8M 11M 10M 10M 9M
changeInWorkingCapital 18M -33M 6M -26M -9M -12M 9M -430 000 164 000
accountsReceivables 6M -57M -4M -33M 0 0 0 0 0
inventory -4M 530 000 -2M -492 000 0 0 0 0 0
accountsPayables 91 000 784 000 727 000 -222 000 -360 000 374 000 107 000 -938 000 -340 000
otherWorkingCapital 16M 22M 12M 8M -9M -12M -107 000 508 000 504 000
otherNonCashItems -1M 71M -238 000 45M -2M -2M -605 000 -488 000 -36 000
netCashProvidedByOperatingActivities 59M -4M 16M -7M -21M -34M -26M -22M -20M
investmentsInPropertyPlantAndEquipment -1M -1M -1M -2M -2M -3M -5M -5M -14M
acquisitionsNet 0 0 0 0 0 0 0 0 0
purchasesOfInvestments -113M -113M -88M -83M -106M -174M -146M -104M -67M
salesMaturitiesOfInvestments 79M 95M 64M 75M 113M 161M 155M 104M 67M
otherInvestingActivites 0 0 0 0 100M 0 0 0 0
netCashUsedForInvestingActivites -34M -19M -26M -10M 105M -16M 4M -5M -15M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 3M 11M 16M 3M 13M 185M 2M 3M 2M
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 3M 11M -5M 0 0 0 -749 000 0 0
netCashUsedProvidedByFinancingActivities 3M 11M 11M 3M 13M 185M 1M 3M 2M
effectOfForexChangesOnCash 286 000 -337 000 187 000 -140 000 12 000 8000 -36 000 -41 000 0
netChangeInCash 28M -13M 678 000 -15M 97M 135M -21M -25M -32M
cashAtEndOfPeriod 374M 346M 359M 358M 373M 276M 141M 162M 186M
cashAtBeginningOfPeriod 346M 359M 358M 373M 276M 141M 162M 186M 219M
operatingCashFlow 59M -4M 16M -7M -21M -34M -26M -22M -20M
capitalExpenditure -1M -1M -1M -2M -2M -3M -5M -5M -14M
freeCashFlow 58M -5M 15M -9M -23M -37M -32M -28M -34M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-04 ET (fiscal 2024 q3)
2024 q1
2024-05-06 ET (fiscal 2024 q1)
2023 q4
2024-02-26 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)

Press-releases

Show financial reports only

2024-11-04 13:00 ET
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates
2024-10-28 11:00 ET
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
2024-09-13 11:00 ET
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
2024-09-06 11:00 ET
Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
2024-08-28 11:00 ET
Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté
2024-08-05 12:00 ET
Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates
2024-07-26 12:00 ET
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
2024-06-05 11:00 ET
Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-15 11:00 ET
Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
2024-05-08 11:00 ET
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
2024-05-06 12:00 ET
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
2024-05-02 11:00 ET
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
2024-04-26 11:00 ET
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
2024-04-22 11:00 ET
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
2024-04-04 11:00 ET
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
2024-02-28 12:00 ET
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
2024-02-26 13:00 ET
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
2024-02-20 12:00 ET
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
2024-02-13 12:00 ET
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
2024-02-08 12:00 ET
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
2024-02-01 12:00 ET
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
2024-01-04 12:00 ET
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
2023-12-19 12:00 ET
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
2023-11-27 12:00 ET
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
2023-11-09 12:00 ET
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
2023-11-06 12:00 ET
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
2023-10-30 11:00 ET
Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
2023-09-28 11:00 ET
Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
2023-09-21 13:00 ET
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
2023-09-07 11:00 ET
Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-09-05 11:00 ET
Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
2023-08-21 11:00 ET
Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million
2023-08-07 11:00 ET
Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights
2023-07-26 20:14 ET
Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707
2023-07-03 11:00 ET
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis
2023-06-05 11:00 ET
Krystal Biotech to Present at Upcoming Investor Conferences
2023-05-23 20:05 ET
Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™
2023-05-22 11:00 ET
Krystal Biotech Announces $160 Million Private Placement Equity Financing
2023-05-19 17:57 ET
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
2023-05-08 12:23 ET
Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights
2023-04-24 11:00 ET
Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program
2023-04-18 11:00 ET
Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest
2023-04-13 11:00 ET
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
2023-03-06 12:00 ET
Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
2023-03-02 12:00 ET
Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference
2023-02-27 12:00 ET
Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
2023-01-18 12:00 ET
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
2023-01-09 13:00 ET
Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa
2022-12-14 22:00 ET
New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa
2022-12-05 12:00 ET
Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
2022-12-01 12:00 ET
Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
2022-11-23 12:00 ET
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
2022-11-17 12:00 ET
Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles
2022-11-07 12:00 ET
Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
2022-09-29 11:00 ET
Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
2022-09-21 20:30 ET
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
2022-09-21 20:30 ET
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
2022-09-08 11:00 ET
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
2022-08-18 21:00 ET
FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa
2022-08-08 11:00 ET
Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
2022-08-01 22:39 ET
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
2022-08-01 11:00 ET
Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
2022-07-06 11:00 ET
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
2022-06-22 11:00 ET
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
2022-06-07 11:00 ET
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
2022-05-19 23:30 ET
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
2022-05-09 20:15 ET
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
2022-05-03 11:00 ET
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
2022-04-11 11:00 ET
Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
2022-03-28 15:00 ET
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
2022-03-26 16:00 ET
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
2022-03-24 11:00 ET
Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
2022-03-18 11:00 ET
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
2022-03-15 11:00 ET
Krystal Biotech Announces Settlement with PeriphaGen, Inc.
2022-02-28 12:00 ET
Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress
2022-02-24 12:00 ET
Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
2022-01-18 12:00 ET
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
2021-12-01 01:15 ET
Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock
2021-11-29 21:20 ET
Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock
2021-11-29 12:00 ET
Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa
2021-11-19 12:00 ET
Jeune Aesthetics to Present Pre-clinical Data Highlighting the Potential of KB303 in Elastin Production at the ASDS 2021 Virtual Meeting
2021-11-08 12:00 ET
Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress
2021-10-26 11:00 ET
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
2021-10-19 20:05 ET
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis
2021-10-14 11:00 ET
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT
2021-10-01 20:01 ET
Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
2021-09-29 12:00 ET
Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis
2021-09-15 12:00 ET
Krystal Biotech Appoints Laurent Goux as General Manager of Europe
2021-09-09 12:00 ET
Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021
2021-09-07 20:31 ET
Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-09 12:00 ET
Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress
2021-07-01 20:15 ET
Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis
2021-06-03 12:00 ET
Krystal Biotech to Participate in Upcoming Investor Conferences
2021-05-10 12:00 ET
Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress
2021-05-03 12:00 ET
Krystal Biotech Appoints Andy Orth as Chief Commercial Officer
2021-04-27 20:35 ET
Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT
2021-04-26 20:05 ET
Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB
2021-04-19 12:00 ET
Krystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline
2021-03-30 12:00 ET
Krystal Biotech Announces Completion of Patient Enrollment in the GEM-3 Pivotal Trial of B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
2021-03-29 20:30 ET
Krystal Biotech to Participate in Upcoming Investor Conferences
2021-03-24 11:00 ET
Krystal Biotech Announces Launch of Jeune, a Gene-Based Aesthetics Company, and Initial Phase 1 Safety Data for KB301 in Aesthetic Indications
2021-03-01 13:37 ET
Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-23 13:00 ET
Krystal Biotech to Present at the Cowen 41st Annual Health Care Conference
2021-02-03 01:50 ET
Krystal Biotech Announces Pricing of Upsized $125 Million Public Offering of Common Stock
2021-02-02 21:10 ET
Krystal Biotech Announces Proposed $100 Million Public Offering of Common Stock
2021-01-04 13:00 ET
Krystal Biotech Appoints Dr. Chris Mason and Dr. Jing Marantz to its Board of Directors
2020-11-24 13:00 ET
Krystal Biotech to Present at the Evercore ISI HealthCONx Conference
2020-11-09 13:00 ET
Krystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress
2020-10-16 20:10 ET
Krystal Biotech Announces Departure of Chief Commercial Officer
2020-10-08 20:10 ET
Krystal Biotech to Present Pre-clinical Data Highlighting KB301 for Aesthetic Indications at the ASDS 2020 Virtual Meeting
2020-09-24 12:00 ET
Krystal Biotech to Present at Upcoming Investor Conferences
2020-09-09 12:00 ET
Krystal Biotech to Present at HC Wainwright and Morgan Stanley Healthcare Conferences
2020-08-25 12:00 ET
Krystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aesthetic Indications
2020-08-17 20:01 ET
Krystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis
2020-08-10 12:00 ET
Krystal Biotech Reports Second Quarter 2020 Financial Results and Provides Update on Operational Progress
2020-07-30 12:00 ET
Krystal Biotech to Present at the William Blair BioTech Conference
2020-07-28 20:44 ET
Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa
2020-07-20 12:00 ET
Krystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business Development
2020-06-08 20:01 ET
Krystal Biotech to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
2020-05-19 01:57 ET
Krystal Biotech Announces Pricing of $125 Million Public Offering of Common Stock
2020-05-18 20:15 ET
Krystal Biotech Announces Proposed Public Offering of Common Stock
2020-05-14 12:00 ET
Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)
2020-05-04 12:00 ET
Krystal Biotech Reports First Quarter 2020 Financial Results and Provides Update on Operational Progress
2020-03-10 12:00 ET
Krystal Biotech Reports 2019 Financial Results and Business Progress
2020-02-25 13:00 ET
Krystal Biotech Announces Change in Financial Leadership
2020-02-21 13:00 ET
Krystal Biotech to Present at the Cowen 40th Annual Healthcare Conference
2020-01-24 13:00 ET
Krystal Biotech Breaks Ground On Second Commercial Gene Therapy Manufacturing Facility
2020-01-21 13:00 ET
Krystal Biotech Appoints Jennifer Chien as Chief Commercial Officer
2019-11-26 13:00 ET
Krystal Biotech to Present at the Piper Jaffray 31st Annual Healthcare Conference
2019-11-04 13:00 ET
Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results
2019-10-29 12:00 ET
Krystal Biotech Announces Final Update from Phase 1/2 Clinical Trial of KB103 ("bercolagene telserpavec," "B-VEC")
2019-10-10 12:00 ET
Krystal Biotech Receives Positive EMA Opinion on Orphan Designation for KB105 to Treat Patients With TGM1 Deficient Autosomal Recessive Congenital Ichthyosis
2019-09-30 12:00 ET
Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference
2019-09-27 12:00 ET
Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent
2019-03-12 12:00 ET
Krystal Biotech Reports 2018 Financial Results and Business Progress
2019-03-06 13:00 ET
Krystal Biotech Continues Vertical Integration with Official Inauguration of Ancoris Gene Therapy Manufacturing Facility at its Pittsburgh Headquarters
2019-03-04 13:00 ET
Krystal Strengthens Board of Directors with Appointment of Julian S. Gangolli

SEC forms

Show financial reports only

SEC form 8
2025-05-06 12:09 ET
Krystal Biotech published news for 2025 q1
SEC form 8
2025-05-06 12:09 ET
Krystal Biotech published news for 2025 q1
SEC form 10
2025-05-06 12:08 ET
Krystal Biotech reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Krystal Biotech published news for 2025 q1
SEC form 10
2025-02-19 00:00 ET
Krystal Biotech reported for 2024 q4
SEC form 10
2024-11-04 08:05 ET
Krystal Biotech reported for 2024 q3
SEC form 8
2024-11-04 08:04 ET
Krystal Biotech published news for 2024 q3
SEC form 8
2024-11-04 08:04 ET
Krystal Biotech published news for 2024 q3
SEC form 10
2024-08-05 08:08 ET
Krystal Biotech reported for 2024 q2
SEC form 8
2024-08-05 08:03 ET
Krystal Biotech published news for 2024 q2
SEC form 8
2024-08-05 08:03 ET
Krystal Biotech published news for 2024 q2
SEC form 10
2024-08-05 00:00 ET
Krystal Biotech published news for 2024 q2
SEC form 10
2024-05-06 08:17 ET
Krystal Biotech published news for 2024 q1
SEC form 8
2024-05-06 08:04 ET
Krystal Biotech published news for 2024 q1
SEC form 8
2024-05-06 08:04 ET
Krystal Biotech reported for 2024 q1
SEC form 10
2024-05-06 00:00 ET
Krystal Biotech published news for 2024 q1
SEC form 8
2024-02-26 08:04 ET
Krystal Biotech published news for 2023 q4
SEC form 8
2024-02-26 08:04 ET
Krystal Biotech published news for 2023 q4
SEC form 10
2024-02-26 07:49 ET
Krystal Biotech reported for 2023 q4
SEC form 10
2024-02-26 00:00 ET
Krystal Biotech published news for 2023 q4
SEC form 8
2023-11-06 07:10 ET
Krystal Biotech reported for 2023 q3
SEC form 10
2023-11-06 07:08 ET
Krystal Biotech reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Krystal Biotech reported for 2023 q3
SEC form 6
2023-08-07 08:18 ET
Krystal Biotech published news for 2023 q2
SEC form 6
2023-08-07 07:13 ET
Krystal Biotech reported for 2023 q2
SEC form 10
2023-08-07 07:07 ET
Krystal Biotech reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Krystal Biotech reported for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Krystal Biotech reported for 2023 q2
SEC form 6
2023-07-26 16:01 ET
Krystal Biotech published news for 2023 q2
SEC form 10
2023-05-08 00:00 ET
Krystal Biotech reported for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Krystal Biotech reported for 2023 q1
SEC form 6
2023-03-09 18:26 ET
Krystal Biotech published news for 2022 q4
SEC form 6
2023-03-06 16:33 ET
Krystal Biotech published news for 2022 q4
SEC form 6
2023-02-27 07:25 ET
Krystal Biotech reported for 2022 q4
SEC form 10
2023-02-27 07:14 ET
Krystal Biotech reported for 2022 q4
SEC form 10
2023-02-27 00:00 ET
Krystal Biotech reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
Krystal Biotech reported for 2022 q4
SEC form 6
2023-01-09 08:55 ET
Krystal Biotech published news for 2022 q4
SEC form 6
2022-11-17 08:33 ET
Krystal Biotech published news for 2022 q3
SEC form 6
2022-11-07 16:14 ET
Krystal Biotech reported for 2022 q3
SEC form 10
2022-11-07 07:11 ET
Krystal Biotech reported for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Krystal Biotech reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Krystal Biotech reported for 2022 q3
SEC form 6
2022-11-03 16:52 ET
Krystal Biotech published news for 2022 q3
SEC form 6
2022-08-18 17:02 ET
Krystal Biotech published news for 2022 q2
SEC form 6
2022-08-08 16:30 ET
Krystal Biotech reported for 2022 q2
SEC form 10
2022-08-08 07:50 ET
Krystal Biotech reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
Krystal Biotech reported for 2022 q2
SEC form 8
2022-08-08 00:00 ET
Krystal Biotech reported for 2022 q2
SEC form 6
2022-06-22 08:41 ET
Krystal Biotech published news for 2022 q1
SEC form 6
2022-05-26 16:34 ET
Krystal Biotech published news for 2022 q1
SEC form 6
2022-05-23 16:20 ET
Krystal Biotech published news for 2022 q1
SEC form 6
2022-05-20 08:26 ET
Krystal Biotech published news for 2022 q1
SEC form 6
2022-05-09 16:19 ET
Krystal Biotech reported for 2022 q1
SEC form 10
2022-05-09 16:07 ET
Krystal Biotech reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Krystal Biotech reported for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Krystal Biotech reported for 2022 q1
SEC form 6
2022-04-07 16:14 ET
Krystal Biotech published news for 2022 q1
SEC form 6
2022-03-28 16:06 ET
Krystal Biotech published news for 2021 q4
SEC form 6
2022-03-22 16:40 ET
Krystal Biotech published news for 2021 q4
SEC form 6
2022-03-15 16:14 ET
Krystal Biotech published news for 2021 q4
SEC form 6
2022-02-28 17:11 ET
Krystal Biotech published news for 2021 q4
SEC form 10
2022-02-28 07:30 ET
Krystal Biotech published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Krystal Biotech reported for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Krystal Biotech published news for 2021 q4
SEC form 6
2022-01-18 16:06 ET
Krystal Biotech published news for 2021 q4
SEC form 6
2021-12-03 16:05 ET
Krystal Biotech published news for 2021 q3
SEC form 6
2021-11-29 16:06 ET
Krystal Biotech published news for 2021 q3
SEC form 6
2021-11-08 16:43 ET
Krystal Biotech published news for 2021 q3
SEC form 10
2021-11-08 07:10 ET
Krystal Biotech published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Krystal Biotech reported for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Krystal Biotech published news for 2021 q3
SEC form 6
2021-09-16 16:33 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-08-19 16:49 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-08-09 16:02 ET
Krystal Biotech published news for 2021 q2
SEC form 10
2021-08-09 08:07 ET
Krystal Biotech reported for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Krystal Biotech published news for 2021 q2
SEC form 8
2021-08-09 00:00 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-08-02 16:39 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-07-07 16:41 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-07-01 17:31 ET
Krystal Biotech published news for 2021 q2
SEC form 6
2021-05-24 16:05 ET
Krystal Biotech published news for 2021 q1
SEC form 6
2021-05-11 19:31 ET
Krystal Biotech published news for 2021 q1
SEC form 6
2021-05-10 08:20 ET
Krystal Biotech published news for 2021 q1
SEC form 10
2021-05-10 08:06 ET
Krystal Biotech published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Krystal Biotech reported for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Krystal Biotech published news for 2021 q1
SEC form 6
2021-04-06 16:30 ET
Krystal Biotech published news for 2021 q1
SEC form 6
2021-03-24 07:00 ET
Krystal Biotech published news for 2020 q4
SEC form 10
2021-03-01 08:21 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-03-01 08:15 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-02-05 16:39 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-02-02 16:01 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-01-07 08:02 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-01-05 17:05 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-01-05 17:03 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2021-01-04 08:15 ET
Krystal Biotech published news for 2020 q4
SEC form 6
2020-12-31 17:28 ET
Krystal Biotech published news for 2020 q3
SEC form 6
2020-11-09 08:32 ET
Krystal Biotech published news for 2020 q3
SEC form 10
2020-11-06 18:41 ET
Krystal Biotech published news for 2020 q3
SEC form 6
2020-10-01 16:06 ET
Krystal Biotech published news for 2020 q3